D59.9: Acquired hemolytic anemia, unspecified
D59.9, acquired hemolytic anemia, unspecified, is listed as a covered diagnosis in 3 Medicare billing and coding articles that apply to 18 HCPCS Level II codes, including J1569 (Injection, immune globulin, (gammagard liquid/gammagard…), J1561 (Injection, immune globulin, (gamunex-c/gammaked)…), J1459 (Injection, immune globulin (privigen), intravenous…). The articles come from 2 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with D59.9 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| J1569 | Injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg | Special coverage instructions apply | — | 2 |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Special coverage instructions apply | — | 2 |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | Carrier judgment | — | 2 |
| J1576 | Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg | Special coverage instructions apply | — | 2 |
| J1557 | Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg | Carrier judgment | — | 2 |
| J1556 | Injection, immune globulin (bivigam), 500 mg | Carrier judgment | — | 2 |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Carrier judgment | — | 2 |
| J1566 | Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | Special coverage instructions apply | — | 2 |
| J1554 | Injection, immune globulin (asceniv), 500 mg | Carrier judgment | — | 2 |
| J1599 | Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg | Carrier judgment | — | 2 |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | Special coverage instructions apply | — | 1 |
| J1552 | Injection, immune globulin (alyglo), 500 mg | Carrier judgment | — | 1 |
| J2792 | Injection, rho d immune globulin, intravenous, human, solvent detergent, 100 iu | Special coverage instructions apply | — | 1 |
| J1577 | Injection, immune globulin (qivigy), 100 mg | Carrier judgment | — | 1 |
| J9312 | Injection, rituximab, 10 mg | Special coverage instructions apply | — | 1 |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Carrier judgment | — | 1 |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Carrier judgment | — | 1 |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Special coverage instructions apply | — | 1 |
Medicare policy articles listing D59.9
- A56718: Billing and Coding: Intravenous Immunoglobulin (IVIG) (Palmetto GBA (MAC - Part A, MAC - Part B); 13 Level II codes). LCD with the same title: L34580
- A59105: Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG) (Wellpoint Federal (MAC - Part A, MAC - Part B); 11 Level II codes). LCD with the same title: L39314
- A59101: Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 4 Level II codes). LCD with the same title: L38920, L39297
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other D59 diagnoses (Acquired hemolytic anemia)
- D59.0 — Drug-induced autoimmune hemolytic anemia
- D59.10 — Autoimmune hemolytic anemia, unspecified
- D59.11 — Warm autoimmune hemolytic anemia
- D59.12 — Cold autoimmune hemolytic anemia
- D59.13 — Mixed type autoimmune hemolytic anemia
- D59.19 — Other autoimmune hemolytic anemia
- D59.30 — Hemolytic-uremic syndrome, unspecified
- D59.31 — Infection-associated hemolytic-uremic syndrome
Frequently asked questions
Does Medicare cover D59.9 (Acquired hemolytic anemia, unspecified)?
Medicare covers items and services, not diagnoses. 3 Medicare billing and coding articles list D59.9 as a covered diagnosis for 18 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 D59.9?
The Level II codes from the policies most specific to this diagnosis are J1569 (Injection, immune globulin, (gammagard liquid/gammagard…, 2 articles); J1561 (Injection, immune globulin, (gamunex-c/gammaked)…, 2 articles); J1459 (Injection, immune globulin (privigen), intravenous…, 2 articles); J1576 (Injection, immune globulin (panzyga), intravenous…, 2 articles); J1557 (Injection, immune globulin, (gammaplex), intravenous…, 2 articles). Code choice depends on the item supplied; check each code's descriptor.
Which Medicare policy articles list D59.9?
A56718 (Billing and Coding: Intravenous Immunoglobulin (IVIG)); A59105 (Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG)); A59101 (Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars).
What is ICD-10-CM code D59.9?
D59.9 is the ICD-10-CM code for acquired hemolytic anemia, unspecified, in category D59 (Acquired hemolytic anemia), chapter 3: Diseases of the blood and immune mechanism.
Next steps
- Run a reimbursement report for a device billed under J1569
- Watch J1569 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1569
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.
Chapter 3: Diseases of the blood and immune mechanism · All diagnoses · HCPCS lookup